Recent breakthroughs in Alzheimer’s disease research bring new hope to patients and their families. One significant development occurred in June when Tiziana Life Sciences gained FDA clearance to administer intranasal foralumab to its first patient with moderate Alzheimer’s disease. This milestone, part of the FDA’s expanded access investigational new drug program, marks a promising step forward.

Promising Approach to Slowing Cognitive Decline

Howard L. Weiner, MD, principal investigator and chairman of Tiziana’s Scientific Advisory Board, expressed enthusiasm for the treatment’s potential. He highlighted its ability to target neuroinflammation caused by toxic protein buildup in the brain, stating, “Given that nasal foralumab dampens microglial inflammation in subjects with advanced progressive MS and microglial activation is a prominent feature of Alzheimer’s disease, Tiziana is hopeful that nasal foralumab will help slow the progression of cognitive decline in this first patient.” Continue reading FDA Greenlights Nasal Spray for Alzheimer’s Disease